29 reports of this reaction
0.6% of all TROSPIUM CHLORIDE reports
#77 most reported adverse reaction
PULMONARY HYPERTENSION is the #77 most commonly reported adverse reaction for TROSPIUM CHLORIDE, manufactured by Padagis US LLC. There are 29 FDA adverse event reports linking TROSPIUM CHLORIDE to PULMONARY HYPERTENSION. This represents approximately 0.6% of all 4,882 adverse event reports for this drug.
TROSPIUM CHLORIDE has an overall safety score of 72 out of 100. Patients taking TROSPIUM CHLORIDE who experience pulmonary hypertension should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
PULMONARY HYPERTENSION is a less commonly reported adverse event for TROSPIUM CHLORIDE, but still significant enough to appear in the safety profile.
In addition to pulmonary hypertension, the following adverse reactions have been reported for TROSPIUM CHLORIDE:
The following drugs have also been linked to pulmonary hypertension in FDA adverse event reports:
PULMONARY HYPERTENSION has been reported as an adverse event in 29 FDA reports for TROSPIUM CHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
PULMONARY HYPERTENSION accounts for approximately 0.6% of all adverse event reports for TROSPIUM CHLORIDE, making it a notable side effect.
If you experience pulmonary hypertension while taking TROSPIUM CHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.